Research and development progress of antibody drugs for idiopathic pulmonary fibrosis

Idiopathic pulmonary fibrosis is a fibrous disease. At present, its pathogenesis has not been fully elucidated and there is no drug with definite therapeutic effect. After four stages of development, antibody drugs are becoming a new hotspot in drug research and development with their own advantages. A number of drugs have entered the stage of clinical trials. Based on this, this review summarizes the antibody drugs for the clinical stage of clinical research of idiopathic pulmonary fibrosis, in order to summarize the development of antibody drugs, and provide certain bases and ideas for the development of antibody drugs.